Democrats such as Elizabeth Warren had their eye on business and the working class during the first 2020 presidential primary debate in Miami.2020 Electionsread more
The issue over health insurance marked the first stark divide among the candidates, and sparked a heated back-and-forth between many of the candidates on stage.Politicsread more
Huawei's legal chief told CNBC that the company makes "solutions for civil use."Technologyread more
Four candidates mentioned China — but none of the Democratic contenders brought up trade in the debate.Politicsread more
In a strategy to draw attention away from Wednesday's Democratic debate, President Donald Trump's reelection campaign bought out YouTube's "masthead," the leading...2020 Electionsread more
The Federal Aviation Administration said on Wednesday that is has found an issue with the Boeing 737 Max that the manufacturer must address before it lifts the grounding...Airlinesread more
The collapse of the deal potentially ended Sinclair's hopes of building a national conservative-leaning TV powerhouse that might have rivaled Fox News.Mediaread more
Virginia Sen. Mark Warner breaks down the idea behind a bipartisan bill he introduced to provide more transparency in Big Tech.Technologyread more
Tesla is working on new battery cell designs, and a way to make their own cells, with R&D teams in a lab near its car plant in Fremont, California.Technologyread more
These attacks have given the public the opportunity to examine the problems associated with ransomware, where corporations -- not obligated to disclose these attacks -- have...Technologyread more
Wi-Fi 6 will be the next-generation wireless standard. Along with 5G, it will represent the next big shift in connectivity and data, said Irving Tan, senior vice president and...Shaping the futureread more
The iShares Nasdaq Biotechnology ETF saw its worst day since Aug. 4, 2011, on Tuesday and is on pace for its worst month since March 2001. However, one analyst remains bullish on biotech despite its recent fall.
Len Yaffe of Stoc*Doc Partners told CNBC's "Closing Bell" that investors can capitalize on opportunities to buy on this significant price decline.
"I think that the multiples have come down for the companies earning money from about 24 times next year's earnings to about 17-18 times, more in line with the S&P, more in line with major pharma," Yaffe said. "And I think there's several companies so specifically where I think the prospects are much better than the analysts expect."
Yaffe said that ETFs, which weren't around a decade ago, have incrementally exacerbated the biotech decline. On the other hand, ETFs have also caused rallies to be stronger, Yaffe added.
"So I think you've seen a lot of confusion in the market ... in this decline, trying to separate out what's real, from a drug-pricing standpoint, versus what probably isn't," he said. "And I think that's left a lot of opportunities down at the current level."
Yaffe named PCSK9 inhibitors, a class of drugs used to lower cholesterol, as a catalyst that will double expected revenues by 2020. Therefore, Yaffe added that he's very favorable towards shares of Regeneron, Amgen, Gilead and Juno.
"I look for areas of major unmet medical need, which I think now is in hepatology, nephrology and oncology, as well as areas where I think the companies or certain drugs will do far better than Wall Street analysts expect," he said.
The IBB closed down 0.39 percent Tuesday at 289.48, inching closer to it's 52-week low of 247.86.
— CNBC's Chris Hayes contributed to this report.